Company intelligence / Profile preview

Tissue Regenix

Leeds, West Yorkshire, United Kingdommarketscreener.com ↗

Ownership: Private
Development stage: Other

Overview

Tissue Regenix has commercialized DermaPure®, a human tissue-derived wound care product using its proprietary dCELL® platform. Clinical adoption in the US has grown due to unique clinical benefits and expanded reimbursement coverage. The company also develops additional regenerative medicine products for orthopedics and dental indications.

Therapeutic areas: DermatologyOther
Modalities: BiologicDecellularized tissue-based products
Industry: Biotech

Partnerships

Arthrex Inc.ARMS MedicalPremier GPOVizient GPOMidCap Financial funding facility

Beyond the preview

Go deeper on Tissue Regenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue Regenix.

Explore the full profile